GlassScriptPhysician profile
Denise Gallo
NPI 1235431560
$4,918.51
in general payments reported to CMS, 2019-2025
23 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,182 · 2022: $501 · 2023: $693 · 2024: $607 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Consulting Fee: $750 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.83 |
| Consulting Fee | $750.00 |
| Education | $434.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $843.69 | 2021-2025 | |
| Genzyme Corporation | $644.53 | 2021-2025 | |
| Janssen Biotech, INC. | $584.84 | 2021-2025 | Tremfya |
| Allergan, INC. | $447.58 | 2021-2022 | |
| Incyte Corporation | $349.12 | 2021-2025 | Opzelura |
| Abbvie INC. | $335.31 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $289.79 | 2021-2025 | Ilumya |
| Almirall LLC | $216.95 | 2021-2022 | |
| Galderma Laboratories, L.P. | $200.91 | 2021 | |
| Amgen INC. | $196.27 | 2021-2024 | Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $128.84 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $113.40 | 2021-2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $95.26 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.30 | 2021-2024 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $60.51 | 2021 | |
| Pfizer INC. | $51.66 | 2021 | |
| Leo Pharma INC. | $47.70 | 2021-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.01 | 2021-2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $32.73 | 2023-2025 | |
| Dermira, INC. | $21.60 | 2021 | |
| Strata Skin Sciences, INC. | $17.22 | 2024 | Xtrac |
| Sebela Pharmaceuticals INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.